Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors
Gilbert Donders(Institut Scientifique de Santé Publique), Olaf Ortmann(University of Regensburg), Patrick Neven(KU Leuven), Stefan Buchholz(University Hospital Regensburg), Gert Bellen(Flemish Community), Philipp Grob, V. Prasauskas
European Journal of Clinical Microbiology & Infectious Diseases
July 29, 2015
Cited by 43
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy
|BJOG An International Journal of Obstetrics & Gynaecology|2009|436